Loading company…
Riskpilot
← Back to search
Sign in
Get full access
OncoSignature AB
AB
In liquidation
Org 5590748470
Other research and experimental development on natural sciences and engineering · NACE 7219
Est. 2016
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2019
SEK 0
EBITDA margin
—
+100% vs 2018
Equity ratio
57.7%
Financial strength
Net profit 2019
SEK -4K
+100% vs 2018
EBITDA — year on year
SEK millions
0M
-1M
-2M
-3M
-4M
-3M
2017
-1M
+67%
2018
0M
+100%
2019
Key figures
Annual report 2019
Revenue
SEK 0
—
EBITDA
SEK -3K
+100%
Net profit
SEK -4K
+100%
Total assets
SEK 52K
-32%
Equity
SEK 30K
-12%
Employees
0
—
Company information
Legal name
OncoSignature AB
Org number
5590748470
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
1 september 2016
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Company purpose
Bolaget skall bedriva läkemedelsutveckling för att optimera design av kliniska prövningar inom onkologi och därmed förenlig verksamhet.
Contact
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Other research and experimental development on natural sciences and engineering
Companies in
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
1M
2017
0M
2018
0M
2019
EBITDA
SEK millions
0M
0M
1M
1M
1M
-3M
2017
-1M
2018
0M
2019
Income statement
SEK thousands
Item
2017
2018
2019
Revenue
1 187
0
0
Staff expenses
—
—
—
EBITDA
−2 722
−1 384
−3
Depreciation & amort.
−7
−2
−0
EBIT
−2 729
−1 386
−3
Net financials
—
−1 800
−1
Profit before tax
−2 729
−3 186
−4
Tax
−0
−0
−0
Net profit
−2 729
−3 186
−4
Balance sheet
SEK thousands
Item
2017
2018
2019
Total assets
3 706
76
52
Equity
3 220
34
30
Long-term debt
0
0
0
Short-term debt
486
42
22
Total debt
486
42
22
Financial ratios
5-year trend
EBITDA margin
-300000.0%
This company
15.8%
Market median
-1898834% vs market
2017
2019
Equity ratio
57.7%
This company
38.2%
Market median
+51% vs market
2017
2019
Return on equity
-13.3%
This company
18.4%
Market median
-172% vs market
2017
2019
Net profit margin
-400000.0%
This company
8.1%
Market median
-4938372% vs market
2017
2019
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2017
2019
Debt / equity
0.73×
This company
0.62×
Market median
+18% vs market
2017
2019
Annual reports & filings
Annual report 2019
Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
View
PDF
Annual report 2017
Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (2)
AH
Annika Heléne Lundeslöf
Liquidator
Liquidator
2020
CA
Curt Arne Jesper Ahlkvist
Audit
Audit
2020
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of OncoSignature AB also hold positions in
0
other companies.
Person
Role here
Other companies
Annika Heléne Lundeslöf
Liquidator
0 companies
Curt Arne Jesper Ahlkvist
Audit
0 companies